- Find the Right Path to Reimbursements
- Learn When to Engage the FDA
- Understand how VCs Mitigate Regulatory/Reimbursement Risk
- Hear how to Stage a Successful Commercial Launch
Dave Amerson, President & CEO – Neotract
Jolayne Devers, MBA, CPC, Principal – JD LYMON Group
Mark DuVal, JD, President – DuVal & Associates
Earl R. Fender, CEO – Vertiflex
William V. Murray, President & CEO – Medical Device Innovation Consortium (MDIC)
Paul Buckman, President & CEO – Conventus Orthopaedics
Mr. Buckman has served as CEO and board member of Conventus Orthopaedics since September 2013. Prior to Conventus, Mr. Buckman also held CEO roles at SentreHeart, Inc. (continues as Director), Pathway Medical Technologies (sold to Bayer Healthcare in 2011), and Devax, Inc. (sold to Biosensors International).
Dave is President and CEO of NeoTract, Inc., a medical device company focused on shifting the treatment paradigm in urology. Under his leadership, NeoTract received FDA De Novo clearance for the UroLift® System, a minimally invasive technology to treat symptoms of benign prostatic hyperplasia (BPH).
Jolayne Devers, MBA, CPC
For over 20 years, Jolayne has worked in the health care industry years in a variety of sectors, including a world-leading medical device company, a large commercial payer, and a provider organization.
Mark DuVal, JD
Mark DuVal, JD, FRAPS, is President of DuVal & Associates, P.A., a law firm dedicated to counseling companies in the medical device, pharmaceutical and nutritional supplement industries.
Earl R. Fender
Mr. Fender has served as the President and CEO since March of 2008. He brings over 25 years of successful leadership experience in general management and product commercialization in the medical device and spinal industry.
William V. Murray
Bill joined MDIC in August of 2013 as the first President and CEO. He has over 25 years of senior leadership experience spanning the range of privately financed start-up to billion dollar plus global businesses.